

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*

# Hutchison Whampoa Limited

*(incorporated in Hong Kong with limited liability)*  
**(Stock Code: 13)**

## OVERSEAS REGULATORY ANNOUNCEMENT

Please refer to the attached announcement of Hutchison China MediTech Limited, which is listed on the Alternative Investment Market operated by the London Stock Exchange and a 71.5% owned subsidiary of Hutchison Whampoa Limited.

As at the date of this announcement, the Directors of the Company are:

**Executive Directors:**

Mr LI Ka-shing (*Chairman*)  
Mr LI Tzar Kuoi, Victor (*Deputy Chairman*)  
Mr FOK Kin-ning, Canning  
Mrs CHOW WOO Mo Fong, Susan  
Mr Frank John SIXT  
Mr LAI Kai Ming, Dominic  
Mr KAM Hing Lam

**Non-executive Directors:**

Mr George Colin MAGNUS  
Mr William SHURNIAK

**Independent Non-executive Directors:**

The Hon Sir Michael David KADOORIE  
Mr Holger KLUGE  
Mrs Margaret LEUNG KO May Yee  
Mr William Elkin MOCATTA  
*(Alternate to The Hon Sir Michael  
David Kadoorie)*  
Mr WONG Chung Hin

Hong Kong, 4 January 2010



HUTCHISON CHINA MEDITECH LTD

**Hutchison China MediTech Limited (“Chi-Med”)  
(AIM: HCM)**

**Total Voting Rights**

**London: Monday, 4 January 2010:** For information purposes, Chi-Med hereby notifies the market that as at 31 December 2009, the issued share capital of the Company consisted of 51,279,174 ordinary shares of US\$1.00 each, with each share carrying one right to vote and with no shares held in treasury.

The above figure of 51,279,174 may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, Chi-Med under the FSA's Disclosure and Transparency Rules.

**Ends**

**Enquiries**

**Chi-Med**  
Christian Hogg, CEO

Telephone: +852 2121 8200

**Citigate Dewe Rogerson**  
Anthony Carlisle  
David Dible

Telephone: +44 (0) 20 7638 9571  
+44 (0) 7973 611 888  
+44 (0) 7967 566 919

**Lazard & Co., Ltd.**  
Paul Gismondi  
Nick Fowler

Telephone: +44 (0) 20 7187 2000

**About Chi-Med**

Chi-Med is the holding company of a pharmaceutical and healthcare group based primarily in China and was admitted to trading on the Alternative Investment Market of the London Stock Exchange in May 2006. It is focused on researching, developing, manufacturing, and selling pharmaceuticals, health supplements and other consumer health and personal care products derived from Traditional Chinese Medicine and botanical ingredients.

Chi-Med is majority owned by Hutchison Whampoa Limited, an international company listed on the Main Board of The Stock Exchange of Hong Kong Limited.